

1 **Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting**  
2 **viral RNA polymerase activity**

3  
4 Tatiana G. Zubkova<sup>1</sup>, Aartjan J.W. te Velhuis<sup>2#</sup>, Megan Shaw<sup>3\*</sup>, Andrew Mehle<sup>4</sup>, David Boltz<sup>5</sup>,  
5 Norbert Gmeinwieser<sup>6</sup>, Holger Stammer<sup>6</sup>, Jens Milde<sup>6</sup>, Lutz Müller<sup>7#</sup>, Victor Margitich<sup>8</sup>

6  
7  
8 <sup>1</sup>Research Institute of Influenza of North-West Branch of Russian Academy of Medical Sciences,  
9 St. Petersburg, Pavlov str., 12, Russian Federation.

10 <sup>2</sup>Division of Virology, Department of Pathology, Addenbrooke's Hospital, University of  
11 Cambridge, Hills Road, CB2 2QQ, United Kingdom.

12 <sup>3</sup>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029,  
13 USA.

14 <sup>4</sup>Department of Medical Microbiology & Immunology, University of Wisconsin-Madison,  
15 Madison, WI 53706, USA.

16 <sup>5</sup>IIT Research Institute, 10 West 35th Street, Chicago, IL 60616, USA.

17 <sup>6</sup>Pharmalog Institut für klinische Forschung GmbH, Ismaning, Germany

18 <sup>7</sup>Dr. Regenold GmbH, Zoellinplatz 4, 79410 Badenweiler, Germany

19 <sup>8</sup>Farmak JSC, 63 Kyrylivska Street, Kyiv, 04080, Ukraine

20

21 # Corresponding authors:

22 Dr. Regenold GmbH, Zoellinplatz 4, 79410 Badenweiler, Germany;

23 Phone: +49 7632 8226-50; Fax: +49 7632 8226-555; E-mail: lutz.mueller@regenold.com

24 Division of Virology, Department of Pathology, Addenbrooke's Hospital, University of  
25 Cambridge, Hills Road, CB2 2QQ, United Kingdom; Phone: +44 1223 763421; Fax: +44 1223  
26 333346; E-mail: ajwt6@cam.ac.uk

27

28 \*present address: Department of Medical Biosciences, University of the Western Cape, Robert

29 Sobukwe Road, Bellville 7535, South Africa

30 **Abstract**

31 Infections with respiratory viruses constitute a huge burden on our health and economy.  
32 Antivirals against some respiratory viruses are available, but further options are urgently needed.  
33 Enisamium iodide (laboratory code FAV00A, trade name Amizon®) is an antiviral marketed in  
34 countries of the Commonwealth of Independent States for the treatment of viral respiratory  
35 infections, but its clinical efficacy and mode of action are not well understood. Here, we  
36 investigated the efficacy of FAV00A in patients aged between 18-60 years with confirmed  
37 influenza and other viral respiratory infections. FAV00A treatment resulted in reduced influenza  
38 virus shedding (at day 3, 71.2% in FAV00A group tested negative versus 25.0% in placebo  
39 group,  $p < 0.0001$ ), faster patient recovery (at day 14, 93.9% in FAV00A group had recovered  
40 versus 32.5 % in placebo group,  $p < 0.0001$ ), and reduced disease symptoms compared to  
41 placebo (from  $9.6 \pm 0.7$  to  $4.6 \pm 0.9$  score points in FAV00A group versus  $9.7 \pm 1.1$  to  $5.6 \pm 1.1$   
42 score points in placebo group,  $p < 0.0001$ ). Using mass-spectrometry, and cell-based and cell-free  
43 viral RNA synthesis assays, we identified a hydroxylated metabolite of FAV00A, VR17-04.  
44 VR17-04 is capable of inhibiting influenza virus RNA synthesis and present in plasma of patients  
45 treated with FAV00A. VR-17-04 inhibits the activity of the influenza virus RNA polymerase  
46 more potently than its parent compound. Overall, these results suggest that FAV00A is  
47 metabolized in humans to an inhibitor of the influenza virus RNA polymerase that reduces viral  
48 shedding and improves patient recovery in influenza patients.

49

50 Clinical data are available on [ClinicalTrials.gov](https://clinicaltrials.gov) under NCT04682444.

51

- 52 **Key words:** treatment, respiratory viruses, influenza A and B viruses, respiratory syncytial virus,  
53 adenovirus, enisamium iodide, FAV00A, RNA polymerase, RNA synthesis.

## 54 **Introduction**

55 Infections with respiratory viruses, such as influenza A virus (IAV), are the cause of morbidity  
56 and mortality in humans, and a source of serious medical and socio-economic problems for  
57 human health worldwide. Of additional concern is the simultaneous circulation of several  
58 respiratory viruses in the human population, including influenza B virus (IBV), adenoviruses  
59 (ADV), parainfluenza viruses (PIV), respiratory syncytial virus (RSV), coronaviruses (CoV), and  
60 various IAV subtypes (e.g., H3N2 and H1N1). All these viruses have the potential to spread  
61 rapidly among the human population, become resistant to antivirals, cause severe disease, and be  
62 associated with secondary complications (1). Moreover, novel respiratory viruses may emerge  
63 from animal reservoirs, such as wild birds or bats, and cause a pandemic when no or little pre-  
64 existing immunity exists in the human population. Examples of recent outbreaks are the SARS-  
65 CoV-2 pandemic virus in 2019-2020 and the H1N1 pandemic IAV strain in 2009-2010.  
66 Together, these characteristics make respiratory viruses a major threat to human health and  
67 extraordinarily difficult target for the development of preventive and therapeutic mitigation  
68 measures.

69 Seasonal IAV and IBV infections can be prevented by inactivated or live attenuated  
70 vaccines. Vaccines have also been approved for emerging highly pathogenic IAV H5N1 or H7N9  
71 strains, and pandemic SARS-CoV-2. However, the efficacy of these vaccines is dependent upon  
72 antigenic similarity between the vaccine strain and the circulating viruses, and potentially  
73 diminished in high-risk groups (2, 3). Furthermore, the lead-time to produce new vaccines is  
74 long. Currently, no vaccines exist against human seasonal CoV or RSV infections, although  
75 vaccines are in development (4-6).

76 Drug-based antiviral therapies are an important mitigation strategy against respiratory  
77 virus infections. In the case of IAV infections, drugs are available that target the viral  
78 neuraminidase protein (e.g., oseltamivir, zanamivir, peramivir and lanamivir), the IAV RNA-  
79 dependent RNA polymerase (e.g., favipiravir) or the endonuclease domain of PA protein  
80 (baloxavir marboxil) (7, 8). Emergence of resistant viruses has been reported for most of these  
81 antivirals (9, 10) and research into alternative antiviral therapies with a different mode of action  
82 is needed.

83 Enisamium is an isonicotinic acid derivative. The iodide salt of enisamium (FAV00A),  
84 formerly named carbabenzpyride, is marketed as Amizon® in 11 countries, including in former  
85 Soviet Union countries and Mongolia, for the prophylaxis and treatment of influenza and other  
86 viral diseases in adults and children (11). Previous studies indicate that FAV00A inhibits IAV  
87 and IBV replication in cell culture (12).

88 IAVs and IBV are negative-sense RNA viruses whose 14 kb genome consists of eight  
89 segments of single-stranded viral RNA (vRNA). The viral RNA-dependent RNA polymerase  
90 copies the vRNA into a replicative intermediate called the complementary RNA (cRNA) during  
91 viral replication, or into capped and polyadenylated viral messenger RNA (mRNA) during viral  
92 transcription (13). The cRNA serves as a template for the production of new vRNA molecules.  
93 vRNA and cRNA molecules are both replicated in the context of ribonucleoproteins (RNPs),  
94 which consist of a copy of the RNA polymerase complex bound to the 5' and 3' ends of a  
95 genome segment and a helical coil of nucleoproteins (NPs) that are bound to the rest of the  
96 vRNA or cRNA (13). The IAV and IBV RNA-dependent RNA polymerases are composed of  
97 three subunits: polymerase basic 1 (PB1) protein, PB2 protein, and polymerase acidic (PA)  
98 protein. All three protein subunits are essential for replication and transcription of the viral RNA  
99 genome segments (13).

100 Here we present a comprehensive analysis of the efficacy of FAV00A against IAV *in*  
101 *vitro*, and IAV and IBV infections in patients. We find that FAV00A is effective in reducing viral  
102 shedding and improving patient recovery in influenza infected patients. Subsequent mass-  
103 spectroscopy analysis of sera from FAV00A-treated patients revealed the presence of a  
104 hydroxylated metabolite of FAV00A, VR17-04. Using cell-free RNA polymerase activity  
105 experiments, we show that the metabolite VR17-04 is a more potent inhibitor of influenza A viral  
106 RNA synthesis than FAV00A. Overall, these results suggest that FAV00A is effective in  
107 reducing virus shedding and improving recovery of influenza patients, and its mode of action is  
108 inhibition of the influenza virus RNA polymerase most likely via the active metabolite VR17-04.

109

## 110 **Materials and methods**

### 111 *Ethics of clinical study*

112 To investigate efficacy and tolerability of FAV00A in patients infected with respiratory viruses, a  
113 prospective, single-blinded, placebo-controlled, single-center clinical trial was performed. The  
114 study was conducted in accordance with the Declaration of Helsinki, ICH-GCP and the national  
115 laws and regulations in the Research Institute of Influenza of the North-West Branch of the  
116 Russian Academy of Medical Sciences (NWB RAMS), St. Petersburg, Russian Federation,  
117 between 2009 and 2010. The study was approved by the Ethics Commission of the Research  
118 Institute of Influenza of the NWB RAMS (Extract of report No 28 of 09 April 2009) after review  
119 of the clinical trial protocol, Investigator's Brochure, patient information with informed consent,  
120 case report forms, insurance policy, and the qualifications of the investigator. Patients provided a  
121 written informed consent prior to study participation.

122

123 *Sample size of clinical study*

124 A sample size calculation was performed to design the clinical trial. The maximal difference  
125 between pre- and post-treatment parameters that was considered not significant was set to 0.25.  
126 Thus, a sample size of 30 patients in both the FAV00A- and placebo-treated groups would be  
127 needed to demonstrate an efficacy of FAV00A with a statistical power of 90% (bilateral) and a  
128 confidence level of 5%. We further estimated that about 15% of the patients would withdraw or  
129 be withdrawn (see exclusion criteria below) from the study prior to its completion. Using Fisher's  
130 exact test for subsequent analyses, we estimated that a starting cohort of 50 patients per group  
131 would be sufficient to achieve the statistical power stated above.

132

133 *Patient cohort and treatment during the clinical study*

134 Male and female patients aged between 18 and 60 years with viral respiratory infections were  
135 eligible for participation in the clinical study. The diagnosis of viral respiratory infection was  
136 based on axillary body temperature  $\geq 37.2^{\circ}\text{C}$ , the presence of at least one symptom of respiratory  
137 tract affection (rhinitis, pharyngitis, laryngitis, tracheitis, bronchitis, cough), and one general  
138 infection symptom (weakness, malaise, myalgia, headache, fever, decreased appetite). In  
139 addition, diagnosis was confirmed by viral antigen immunofluorescence testing of nasal swabs.  
140 Patients with any acute organ dysfunction, serious chronic disease, pregnancy, or breastfeeding  
141 obligations were excluded from clinical trial participation. Patients were recruited by  
142 advertisements, randomized into two groups, and treated with either FAV00A (500 mg three  
143 times daily) or matching placebo for 7 days. Daily dosage and duration of treatment were in  
144 accordance with the summary of product characteristics of FAV00A. The use of  
145 immunomodulatory drugs, systemic sympathomimetics, antipyretics, analgesics, and antibiotics

146 was prohibited during the clinical trial, unless it was required for intervention. Endpoints of the  
147 study were the dynamics of clinical signs by investigating the disappearance of signs of rhinitis  
148 and the decrease of body temperature, interferon status and reduction of the time to recovery.

149

#### 150 *Data collection in clinical study*

151 During the course of the clinical trial, 4 visits were scheduled for each patient: a baseline visit  
152 (day 0) and three follow-up visits 3, 7 and 14 days thereafter. Objective disease symptoms were  
153 assessed by the investigator and subjective symptoms by the patients during each visit. The  
154 objective symptoms comprised fever (i.e., body temperature  $\geq 37.2^{\circ}\text{C}$ ), pharyngeal hyperemia,  
155 conjunctival infection, enlarged lymph nodes, abnormal arterial blood pressure, and auscultation  
156 findings (lung and heart). The subjective symptoms included weakness, myalgia, headache,  
157 increased body temperature (i.e., subjective severity rating), chills, sore throat and cough. All  
158 patients were monitored for adverse events throughout the course of the clinical trial.

159 A score system was used to assess patient health. Objective symptoms were scores as  
160 follows: normal or abnormal blood pressure was counted 0 or 4 score points; lung auscultation  
161 was counted 0 for vesicular breath sound and wheezing or crepitation were scored 2 or 4 points,  
162 respectively; clear and rhythmic heart sounds were each scored 0 points, whereas noisy and  
163 arrhythmic heart sounds were scored 2 points each. The subjective symptoms were assessed  
164 using a 4-point Likert scale, ranging from 1 (absent) to 4 (severe). After patient assessment, a  
165 sum score was calculated. These scores ranged from 4 to 28 (minimum/maximum) for objective  
166 symptoms and from 7 to 28 score point for subjective symptoms.

167 In addition to scoring patient's health, information about the number of days since day 0  
168 without routine activities due to respiratory infection and overall treatment efficacy (complete,



169 significant or moderate improve, no significant change, worsened) was recorded by the patient  
170 and investigator. Finally, nasal swabs were collected from the patients on days 0, 3 and 7 to  
171 determine viral antigen levels by viral antigen immunofluorescence testing.

172

### 173 *Statistical analysis*

174 Descriptive summary statistics were used for analyses of the clinical results. Patients with any  
175 after baseline efficacy and/or safety data were included in the respective analysis set. Continuous  
176 variables were described by mean, median, standard deviation (SD), minimum, as well as  
177 maximum, and categorical variables by absolute numbers and percentages. Interferential analyses  
178 were performed as primary comparison for categorical endpoints evaluated in a by-visit-manner.  
179 For categorical non-binary endpoints, separate van Elteren test stratified by baseline status was  
180 applied per visit or overall, whatever was applicable. If approximation of the chi-square  
181 distribution was not given, Fisher's exact test was used for testing without adjustment for  
182 baseline status. For continuous endpoints collected over time, a mixed model repeated  
183 measurement was used with considered endpoint as dependent variable, baseline as covariate and  
184 treatment, visit and time multiplied by visit as fixed effects. Subgroup analyses by antigen type  
185 (IAV or IBV, IAV alone, IBV alone, ADV alone, a combination influenza/adenovirus, and  
186 others) were performed for selected efficacy parameters as described in the results section.

187

### 188 *Metabolite screening during pharmacokinetic study*

189 To investigate the metabolization of FAV00A in humans, plasma samples were obtained from  
190 participants in a study aimed to investigate the influence of food intake on the pharmacokinetics  
191 of a single dose of FAV00A and conducted in the Vienna General Hospital at the Medical

192 University of Vienna, Vienna, in 2009/2010. The study was performed in accordance with the  
193 Declaration of Helsinki, ICH-GCP and Austrian clinical trial law (EudraCT No. 2009-015382-  
194 32), and approved by the Ethics Commission of the Medical University Vienna and the General  
195 Hospital Vienna (reference no. 868/2009, dated 27 November 2009) after review of the clinical  
196 trial protocol, Investigator's Brochure, patient information with informed consent, insurance  
197 policy, and qualification of the investigator. Patients were recruited from the database of the  
198 study site. During the study, 24 healthy volunteers were randomized and assigned to two groups  
199 in a cross-over design: fasting/fed, fed/fasting. Plasma samples (3 ml, K<sub>3</sub>EDTA Greiner-one  
200 Biotubes) were taken pre-dose (0 h) and following dosing at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2,  
201 2.5, 3, 3.5, 4, 6, 8, 12, 16, 24 and 48 h and stored at -20° C. For the metabolite screening 12  
202 plasma samples from the fasting group were used.

203 To perform the metabolite analysis, the fixed volume of 50 µl (100 µl for pre-dose) of all  
204 12 subjects at different time-points were pooled [pre-dose, P1 (0.5 + 1 + 1.5), P2 (2 + 2.5 + 3), P3  
205 (3.5 + 4 + 6), P4 (8 + 12 + 16), P5 (24 + 48)] samples. Next, 1 mL of each plasma pool was  
206 precipitated with 3 mL of ethanol/acetonitrile (50 : 50, v/v) at room temperature. Plasma samples  
207 were centrifuged for 20 min at 3360 g at 8° C and the supernatant removed. Each precipitate was  
208 washed twice with 3 mL ethanol/acetonitrile (50 : 50, v/v) and centrifuged again for 20 min at  
209 3360 g at 8° C. The supernatants of each wash step were subsequently combined and centrifuged  
210 again to collect any remaining precipitate. The final precipitate was dried under a stream of  
211 nitrogen and reconstituted in 100 µl water/acetonitrile (90 : 10, v/v). A 10 µl aliquot was further  
212 diluted with 40 µl of water/acetonitrile (90 : 10, v/v) and 10 µl of this solution was injected onto  
213 the high-performance liquid chromatography (HPLC) column.

214 LC separation of metabolites was achieved on a Thermo Hypersil Keystone,  
215 HYPERCARB (2.1 × 150 mm, 5 µm) column utilizing a binary gradient of 0.1 % formic acid

216 in water (solvent A), and 0.1 % formic acid in water/acetonitrile (10 : 90, v/v, solvent B). The  
217 gradient schedule was programmed at 95 : 5 (A : B) for 0 to 1.0 min; 0 : 100 for 30 min, and  
218 95 : 5 for 40 min. The LC flow rate was 200 µl/min. Each sample extract was analyzed by  
219 reverse-phase liquid chromatography with full scan high-resolution mass spectrometry detection.  
220 Experiments were carried out in full scan (positive ion mode, m/z range 120 – 1000, Scan-Event  
221 1).

222 For selected pools, experiments were also carried out in MS/MS mode (Scan-Event 2 – 4).  
223 MS<sup>n</sup> data were recorded in the data dependent mode at single mass resolution. In the MS<sup>n</sup>  
224 experiments, the instrument operated using an inclusion list of all candidates, detected in full  
225 scan. Whenever a compound with the same m/z values as the compounds of the inclusion list was  
226 detected, the instrument automatically switched to MS<sup>n</sup> and collected the fragmentation pattern.  
227 For the linear Ion trap methods, the experiments were carried out in full scan (positive ion mode,  
228 m/z range 120 – 1000, Scan-Event 1) and in MS/MS mode (Scan-Event 2 – 4). For LTQ-  
229 Orbitrap-Method (accurate mass measurements) the experiments were carried out in full scan  
230 mode (positive ion mode, m/z range 120 – 1000) with a resolution of 60'000 at m/z 400.

231  
232 *Cells, FAV00A, influenza virus infections*  
233 Human epithelial lung carcinoma (A549), human rhabdomyosarcoma (RD), human  
234 hepatocellular carcinoma (HepG2), human embryonic kidney (HEK 293T), and Madin-Darby  
235 canine kidney (MDCK) cells were purchased from the American Type Culture Collection  
236 (ATCC, Manassas, VA). Human epithelial adenocarcinoma (Caco-2) cells were kindly provided  
237 by Dr. Martin Walsh (Mount Sinai School of Medicine, New York, NY). All cells were cultured  
238 at 37 °C, 5% CO<sub>2</sub> in DMEM supplemented with 10% fetal calf serum (FBS) and 1% pen/strep.

239 The Caco-2 and HepG2 cells were grown on collagen-coated plates. FAV00A was synthesized  
240 by Farmak and dissolved in DMSO. Favipiravir triphosphate (T-705-TP) was purchased by  
241 Santa-Cruz Biotechnology and dissolved in water.

242 A549 cells were preincubated with varying concentrations of FAV00A in Minimal  
243 Essential Medium (MEM) containing 0.5% FCS at 37 °C for 1 h. Cells were next infected with  
244 influenza A/WSN/33 (H1N1) virus at a multiplicity of infection (MOI) of 0.01 in MEM  
245 containing 0.5% FCS for 1 h. Following infection, the inoculum was removed and replaced with  
246 varying concentrations of FAV00A in MEM containing 0.5% FCS and incubated for 48 h. Plaque  
247 assays were performed on MDCK cells in MEM containing 0.5% FCS with a 1% agarose overlay  
248 and grown for 48 h at 37 °C. Uninfected cells were treated with compounds in parallel for  
249 assessment of toxicity using a CellTiter-Blue kit (Promega).

250 Caco-2, RD and HepG2 cells were pretreated with FAV00A for 6 h prior to infection with  
251 influenza A/WSN/33 (H1N1) virus and reapplied after infection. Supernatants were collected at  
252 48 h post-infection and titers determined by immunofluorescence staining in 96-well plates as  
253 follows. Serial dilutions of the supernatants were made and used to infect monolayers of MDCK  
254 cells in a 96-well plate. After 1 h incubation, the virus was removed and the cells were washed  
255 with PBS, then incubated in post-infection media (DMEM, 0.1% FBS, 0.3% BSA, 1% pen/strep,  
256 1 mg/ml TPCK trypsin) for 6 h at 37 °C. Cells were fixed in 4% paraformaldehyde, washed 3  
257 times in PBS, and permeabilized in 0.5% Triton X-100. Infected cells were stained with a mouse  
258 monoclonal antibody against influenza virus NP (HT103, generated at Mount Sinai School of  
259 Medicine, New York, NY), and detected with a goat anti-mouse secondary antibody labeled with  
260 AlexFluor 488 (Invitrogen). The number of infected cells was quantified on an imaging plate  
261 cytometer (Celigo, Nexcelom), and used to determine the titer (pfu/ml) based on a standard curve

262 from a known titer virus stock. Uninfected cells were treated with compounds in parallel for  
263 assessment of toxicity.

264

265 *Measurement of viral RNA levels in mini-genome assay*

266 HEK 293T cells were transfected with plasmids expressing the subunits of the influenza  
267 A/WSN/33 (H1N1) virus RNA polymerase (pcDNA3-PB1, pcDNA3-PB2, pcDNA3-PA), the  
268 viral nucleoprotein (pcDNA3-NP) and a viral RNA template based on segment 5 (NP-encoding  
269 genome segment) (14, 15). As negative control, PB1 active site mutant (PB1a) was used in which  
270 the active site SDD motif was mutated to SAA (14). FAV00A was added to the cell culture  
271 medium 15 min after transfection. Twenty-four h after transfection, cells were washed in PBS  
272 and the total RNA extracted using Trizol and isopropanol precipitation (16). 5S rRNA, and IAV  
273 vRNA and mRNA steady state levels were subsequently analyzed by radioactive primer  
274 extension and 6% denaturing PAGE as described previously (16). Phosphorimaging was  
275 performed on an FLA7000 Typhoon Scanner (GE Healthcare). GFP experiments were performed  
276 through transfection of pcDNA3-eGFP and measured using a SpectraMax plate reader.

277

278 *Measurement of RNA polymerase activity in a cell-free system*

279 The subunits of the A/WSN/33 (H1N1) influenza virus RNA polymerase with a TAP-tag on PB2  
280 (pcDNA3-PB1, pcDNA3-PB2-TAP, pcDNA3-PA) were expressed in HEK 293T cells and  
281 purified as heterotrimeric complex using IgG sepharose chromatography (16). Next, 0.5 mM  
282 CTP, 0.5 mM UTP, 0.05 mM ATP, 0.01 mM GTP, 0.5 mM ApG, 0.001 mM [ $\alpha$ -<sup>32</sup>P]GTP, T-705  
283 triphosphate, FAV00A and VR17-04 at the concentrations indicated, and 0.5  $\mu$ M 5' and 3' vRNA

284 promoter strands were added to the purified RNA polymerase. After incubation at 30 °C for 15  
285 min, samples were analyzed by 20% denaturing PAGE and autoradiography (14, 16).

286

## 287 **Results**

### 288 *Patient cohort was predominantly infected with influenza A and B viruses*

289 A total of 137 patients were recruited and screened for respiratory virus infections, and 100 were  
290 randomized for treatment with FAV00A (n = 60) or the placebo control (n = 40) (Fig. 1A). Age  
291 and gender distributions were similar between the two groups (Fig. 1B). All patients completed  
292 the trial as per protocol and no dropouts occurred. At the start of the clinical trial, the patients  
293 reported  $1.6 \pm 0.5$  (mean  $\pm$  SD) days without routine activity due to respiratory infection. Antigen  
294 testing showed that the patients treated with FAV00A or placebo were positive for IAV (43.0%),  
295 ADV (16.0%), a combination of IAV and ADV (14.0%), or IBV (12.0%). An additional 8.0% of  
296 patients tested positive for PIV or RSV, whereas 7% of the patients (5% in the FAV00A group  
297 and 10% in the placebo group) were tested negative for IAV, IBV, ADV, PIV or RSV antigens.  
298 Overall, 69% of patients were infected with influenza A and/or B viruses. Both the FAV00A- and  
299 placebo-treated groups had a similar distribution of respiratory viruses (Fig. 1C). Throughout the  
300 study, there was no deviation from the scheduled medication intake, with a mean treatment  
301 duration of  $6.8 \pm 0.8$  days. Topical decongestants were used for a shorter duration of treatment  
302 and by a lower proportion of patients treated with FAV00A, when compared to the placebo group  
303 (23.3%, n = 14 vs. 75%, n = 30). Expectorants were used by all patients in both treatment groups,  
304 but the majority of the FAV00A-treated patients used the drug for 7 days compared to 14 days  
305 for the placebo-treated patients.

306

307 *FAV00A treatment reduces viral antigen levels and improves activity in patients with viral*  
308 *respiratory disease*

309 Antigen testing on day 3, the first visit after initiation of treatment showed that 71.2% (n = 42) of  
310 the patients treated with FAV00A and 25.0% (n = 10) of the placebo group were negative for the  
311 above-mentioned respiratory virus antigens ( $p < 0.0001$ ). On day 7, the second visit after  
312 initiation of treatment, all patients treated with FAV00A tested negative for respiratory virus  
313 antigens, while 82.5% (n = 33) of the placebo control patients tested negative ( $p = 0.0013$ ) (Fig.  
314 2A). The proportion of patients that tested antigen negative on days 3 and 7 after initiation of  
315 treatment was significantly higher ( $p < 0.0001$ ) in the FAV00A-treated group (70.7%, n = 41)  
316 compared to placebo-treated group (25.0%, n = 10). A subgroup analysis indicated a similar  
317 positive effect of the FAV00A treatment when compared to the placebo for patients infected with  
318 IAV or IBV (75.0%, n = 24 and 22.7%, n = 5, respectively) or ADV (71.4%, n = 5 and 12.5%, n  
319 = 1, respectively). Analysis of patient behavior during the clinical study showed that the  
320 proportion of patients with no or just one day without routine activities after the start of the  
321 treatment was higher in the FAV00A-treated group compared to the placebo group. In the latter  
322 group the majority of patients was not able to perform routine activities for two or more days  
323 (Fig. 2B). These group differences were highly significant ( $p < 0.0001$ ).

324

325 *FAV00A treatment reduces objective symptoms in patients with viral respiratory disease*

326 Analysis of the objective symptoms fever, pharyngeal hyperemia and abnormal lung auscultation  
327 contributed mainly to the objective symptom score at the start of the clinical trial on day 0. There  
328 was no difference between the objective symptom scores between the two groups on day 0 ( $9.6 \pm$   
329  $0.7$  for FAV00A group and  $9.7 \pm 1.1$  for placebo). A low proportion of trial participants

330 presented conjunctival infection (22.0%) and enlarged lymph nodes (1.0%) and none had  
331 abnormal auscultation of the heart or arterial blood pressure at enrollment. The decrease in the  
332 objective symptom score from day 0 till day 14 was statistically significant ( $p < 0.0001$ ) in the  
333 FAV00A-treated group (from  $9.6 \pm 0.7$  to  $4.6 \pm 0.9$  score points) when compared to the placebo  
334 group (from  $9.7 \pm 1.1$  to  $5.6 \pm 1.1$  score points). Absence of all objective symptoms was observed  
335 in both patient groups starting from day 7 (Fig. 3A) and a significant increase in the absence of  
336 all 3 symptoms was observed in the FAV00A-treated patients on day 14 (Fig. 3A;  $p < 0.0001$ ).  
337 Fever, pharyngeal hyperemia as well as lung auscultation were similar in both treatment groups  
338 on day 0, and pharyngeal hyperemia as well as lung auscultation resolved significantly faster in  
339 the FAV00A group compared to the placebo group (Fig. 3B-C). Together, these observations  
340 strongly suggest that FAV00A treatment leads to a faster and highly significant reduction in  
341 objective clinical symptoms associated with respiratory virus infections.

342

### 343 *FAV00A treatment reduces subjective symptoms in patients with viral respiratory disease*

344 The subjective symptoms weakness, headache, increased perceived body temperature, sore  
345 throat, and cough were present in all patients on day 0 and contributed most to the mean  
346 subjective symptom score. Less than half of the patients reported myalgia (46.0%,  $n = 46$ ) and  
347 just a few participants had chills (7.0%,  $n = 7$ ) at day 0. However, the subjective symptoms were  
348 predominantly of mild intensity and almost absent on day 3 in both groups, meaning that they  
349 had limited impact on the score.

350 Analysis of the progression of subjective symptoms over time revealed a more  
351 pronounced decrease in subjective symptoms in the FAV00A-treated group compared to the  
352 placebo group at days 3, 7 and 14 after initiation of treatment (Fig. 4). Specifically, we found that



353 by day 14, the score had decreased from  $15.7 \pm 2.2$  to  $7.1 \pm 0.5$  in the FAV00A group compared  
354 to  $15.4 \pm 1.8$  to  $8.0 \pm 1.3$  in the placebo group. The mean group differences were -1.2 score points  
355 on day 7 ( $p < 0.0001$ ) and -0.9 score points each on day 3 ( $p = 0.0065$ ) and day 14 ( $p < 0.0001$ ). In  
356 addition, we found that the absence of all above mentioned subjective symptoms was more  
357 pronounced in the FAV00A-treated group on both day 7 and day 14 compared to the placebo  
358 control (Fig. 4A). We also found that the subjective symptoms that contributed most to the sum  
359 score (i.e., weakness, headache, increased perceived body temperature, sore throat, and cough)  
360 abated faster in the FAV00A-treated group compared to the placebo group (Fig. 4B-F). These  
361 results are also true when treated and non-treated patients suffering from different virus infections  
362 were compared on day 14 (data not shown). These findings suggest that FAV00A treatment has a  
363 positive outcome on clinically relevant subjective symptoms, such as feelings of weakness,  
364 headache, sore throat and coughing.

365

#### 366 *FAV00A treatment leads to faster patient recovery*

367 Next, we analyzed the recovery time of FAV004-treated and placebo-treated patients in terms of  
368 resolution of symptoms and return to premorbid health status. In support of the above described  
369 observations, a complete recovery from symptoms associated with the viral respiratory infections  
370 was reported by 18.3% ( $n = 11$ ) of the patients treated with FAV00A on day 7, while none in the  
371 placebo group had fully recovered on that day. At day 14, 93.3% ( $n = 56$ ) of the FAV00A-treated  
372 patients had fully recovered, whereas only 32.5% ( $n = 13$ ) of patients in the placebo group  
373 returned to normal health status. A significant improvement in the patient's health status was  
374 reported by 60.0% ( $n = 36$ ) of the FAV00A-treated patients compared to 15.0% ( $n = 6$ ) of the  
375 placebo-treated patients on day 3 ( $p < 0.0001$ ). FAV00A treatment led to a significant

376 improvement in patient's health at all three visit days after initiation of treatment (days 3, 7, 14, p  
377 < 0.0001 to p = 0.0018) when compared to the placebo group.

378 While FAV00A treatment generally led to faster patient recovery, 11 adverse events  
379 (AEs) occurred during the clinical trial. Of these, 4 AEs were reported by 4 patients (6.7%)  
380 treated with FAV00A (bitter taste in the mouth in 2 patients; heart burn and burning sensation in  
381 the throat in 1 patient each). The other 7 AEs in the FAV00A-treated patients were of mild  
382 intensity and resolved without additional therapy. Gastrointestinal side effects as reported by 4  
383 patients are mentioned in the Amizon® Drug Product Label (Summary of Product  
384 Characteristics), which suggests that the AEs were related to Amizon®.

385

#### 386 *FAV00A influenza A virus infection in cell culture*

387 Previous *in vitro* experiments showed that FAV00A can inhibit IAV infection in normal human  
388 bronchial epithelial (NHBE) cultures (12). To confirm and extend these results, we incubated  
389 several human cells lines (A549, RD, Caco-2, or HepG2) with FAV00A and subsequently  
390 infected these cell lines with influenza A/WSN/1933 (H1N1) virus using MOIs that were  
391 optimized for each cell line. We found that FAV00A significantly affected WSN titers in A549  
392 cells with an IC<sub>50</sub> of 322 μM, in line with previous observations (Fig. 5A and 5E). Higher IC<sub>50</sub>  
393 values were observed for the RD, Caco-2 and HepG2 cells (Fig. 5B, C, D and E). Selectivity  
394 indexes for FAV00A were >11 for A549, RD, and Caco-2 cells (Fig. 5E), but lower for HepG2  
395 cells due FAV00A's higher cytotoxicity in these cells (Fig. 5D and E). These data confirm that  
396 FAV00A can inhibit influenza A virus infections in a variety of human cell lines derived from  
397 lung, liver, colon and skeletal muscle tissues; however, its antiviral effects are strongly cell-type

398 dependent, with respiratory tract derived cells such as NHBE (12) and A549 cells (Fig. 5A) being  
399 the best target cells for the anti-influenza A inhibitory activity of FAV00A.

400

401 *FAV00A inhibits IAV RNA polymerase activity in cell culture*

402 To test the mechanism of action for FAV00A, experiments were designed to study its activity on  
403 IAV RNA synthesis. For this purpose, an influenza minigenome assay was used as follows: HEK  
404 293T cells were transfected with plasmids expressing the IAV RNA polymerase subunits PB1,  
405 PB2 and PA (pcDNA3-PB1, pcDNA3-PB2, pcDNA3-PA), the viral NP (pcDNA3-NP) and a  
406 vRNA template based on segment 5 (NP-encoding genome segment), all derived from the H1N1  
407 WSN influenza virus (14, 15). After transfection, FAV00A was added to the cell culture medium  
408 at the concentrations indicated in Fig. 6A. Total cellular RNA was extracted 24 h post-  
409 transfection, and IAV replication (vRNA synthesis) activity was determined by radioactive  
410 primer extension analysis (16). FAV00A treatment significantly reduced the replication capacity  
411 of the viral RNA polymerase with an  $IC_{50}$  of 354  $\mu$ M. To estimate the effect of FAV00A on host  
412 cell RNA synthesis, we transfected a plasmid expressing eGFP from a constitutively active CMV  
413 promoter and measured eGFP expression in the cell suspension of FAV00A treated cell cultures  
414 using GFP fluorescence. As a further control, we analyzed the effect of FAV00A treatment on the  
415 ribosomal RNA (rRNA) steady state level. No significant effect on 5S rRNA or GFP expression  
416 levels was observed in the presence of even higher concentrations (>2 mM) of FAV00A (Fig.  
417 6A). Overall, these observations suggest that FAV00A directly affects influenza viral RNA  
418 polymerase activity in cell-based assays.

419

420 *FAV00A weakly inhibits IAV RNA polymerase activity in vitro*

421 To examine the effect of FAV00A on IAV RNA synthesis *in vitro*, we expressed protein A-  
422 tagged RNA polymerase from A/WSN/1933 (H1N1) virus in HEK 293T cells and purified the  
423 heterotrimeric TAP-tagged polymerase complex using IgG sepharose chromatography. We then  
424 performed *in vitro* RNA synthesis assays using a model 14 nucleotide (nt) vRNA template in the  
425 presence of different concentrations of FAV00A, or T-705 triphosphate (Fig. 6B) as a positive  
426 control. In these assays, FAV00A weakly inhibited IAV RNA polymerase activity with an IC<sub>50</sub> of  
427 46.3 mM, while T-705 triphosphate efficiently inhibited the RNA polymerase with mean IC<sub>50</sub> of  
428 0.011 mM (Fig. 6B). This suggests that FAV00A exerts an inhibitory effect on the IAV RNA  
429 polymerase activity *in vitro*, but its inhibitory activity is rather limited.

430

431 *FAV00A is metabolized in humans and metabolite VR17-04 inhibit IAV RNA polymerase activity*

432 The weak inhibition of the IAV RNA polymerase activity by FAV00A is unlikely to be  
433 responsible for the obvious antiviral efficacy of FAV00A observed in cell culture and in patients.  
434 Based on the data obtained with FAV00A treatment in different cell types (Fig. 5), we  
435 hypothesized that a metabolite of FAV00A could be the actual inhibitor of the IAV RNA  
436 polymerase in cell culture. To test this hypothesis, we treated A549 cells with FAV00A for 24 h,  
437 lysed the cells and then performed IAV RNA polymerase activity assays in the presence of the  
438 cellular extract. We observed a strong, concentration-dependent inhibition of IAV RNA  
439 polymerase activity, which is consistent with the hypothesis that a metabolite of FAV00A  
440 inhibits influenza virus RNA synthesis during IAV infection (Fig. 6C).

441 To confirm that FAV00A is metabolized in humans, we analyzed human plasma samples  
442 from a phase I pharmacokinetic study using HPLC and MS/MS. This analysis revealed the  
443 presence of 4 phase I metabolites (Fig. 6D), of which two were hydroxylated (VR17-02 and

444 VR17-04), one was demethylated (VR18-06), and one was both hydroxylated and demethylated  
445 (VR18-05). We also detected phase II metabolites that had been formed by glucuronidation or  
446 sulfate conjugation of phase I metabolites. Since glucuronidation or sulfate conjugation typically  
447 result in drug inactivation, we did not study the phase II metabolites further. In order to test if  
448 FAV00A phase I metabolites have a direct effect on IAV RNA polymerase activity *in vitro*, the  
449 phase I metabolites were synthesized. Only VR17-04 was sufficiently soluble in DMSO for *in*  
450 *vitro* testing and subsequently tested in *in vitro* IAV RNA polymerase assays containing purified  
451 IAV RNA polymerase, a 14-nt long vRNA, ApG, radiolabeled [ $\alpha$ -<sup>32</sup>P]GTP, and all four unlabeled  
452 NTPs (14). Analysis of the reactions by 20% denaturing PAGE revealed a strong inhibition of  
453 viral RNA synthesis in the presence of the hydroxylated metabolite VR17-04 when compared to  
454 the DMSO control (Fig. 6E). Quantitation of the reactions showed that the human metabolite  
455 VR17-04 inhibited IAV RNA polymerase activity 55-fold stronger (IC<sub>50</sub> of 0.84 mM) than  
456 FAV00A (IC<sub>50</sub> of 46 mM) (Fig. 6C).

457

## 458 **Discussion**

459 Infections with respiratory viruses create a huge burden on our health and economy, but currently  
460 only a limited number of antivirals are available against the viruses that cause them. Here, we  
461 investigated the efficacy and safety of FAV00A in patients aged between 18-60 years with  
462 clinically and virologically confirmed influenza and other viral respiratory infections. The  
463 clinical study demonstrated that treatment with FAV00A resulted in reduced virus shedding and a  
464 reduced mean number of days without routine activities in patients with viral respiratory  
465 infections, when compared to placebo. In addition, objective symptoms (fever, pharyngeal  
466 hyperemia) and subjective symptoms (weakness, headache, increased perceived body

467 temperature, sore throat, and cough) were reduced and disappeared more quickly in patients  
468 receiving FAV00A treatment. These results suggest (i) a direct clinical effect of FAV00A on the  
469 outcome of viral respiratory infections in humans and (ii) that FAV00A treatment leads to faster  
470 patient recovery and a reduction of symptoms.

471 The use of concomitant symptomatic therapy (e.g., topical decongestants and  
472 expectorants) as well as the impact of the concomitant medication on the evaluation of the  
473 symptoms could affect clinical trial results. However, in the FAV00A-treated group,  
474 symptomatic drugs were taken less frequently and for shorter durations than in the placebo group,  
475 suggesting that an overestimation of the FAV00A effects due to concomitant symptomatic  
476 therapy can be excluded. In fact, it is tempting to suggest that FAV00A treatment led to reduced  
477 symptomatic therapy in the FAV00A-treated group. Moreover, in recent clinical trials with  
478 influenza virus neuraminidase inhibitors (e.g., oseltamivir), the evaluated symptoms such as  
479 fever, chills, headache, muscle ache, and cough as well as other clinical parameters return to  
480 routine activities, were similar to the symptoms and parameters evaluated in this clinical trial (17,  
481 18). Therefore, the methods used to evaluate the efficacy of FAV00A for human respiratory virus  
482 infections and the results presented here should be reliable.

483 We also evaluated symptoms that are not characteristic for respiratory tract infections  
484 such as abnormal arterial blood pressure, abnormal auscultation findings of the heart, enlarged  
485 lymph nodes, and conjunctival infection. Most of these symptoms were indeed absent in the trial  
486 population or only present in a low percentage of the patients and of mild intensity. These non-  
487 characteristic symptoms were revealed in all or almost all patients on day 3 after initiation of  
488 treatment in both treatment groups, suggesting that these atypical symptoms did not contribute  
489 considerably to the outcome of the clinical trial. The patients included in this study had primarily  
490 mild to moderate respiratory disease. Thus, the efficacy of FAV00A against severe forms of

491 respiratory disease or for high-risk groups of patients need to be confirmed. The results will also  
492 need to be confirmed in a double-blinded clinical trial, since the current study relied on blinded  
493 patients but unblinded investigators. While our study included predominantly patients infected  
494 with influenza viruses or co-infections between influenza viruses and adenovirus, the results  
495 suggest that FAV00A can be effective against other respiratory virus infections. Indeed, results  
496 from another recent study showed that FAV00A inhibits SARS-CoV-2 replication *in vitro* (19).

497         Analysis of serum samples from FAV00A-treated patients revealed a number of FAV00A  
498 metabolites, suggesting that not FAV00A, but one or more metabolites may be inhibiting  
499 respiratory virus infections. A previous study had suggested that FAV00A inhibits influenza  
500 virus RNA synthesis (12). Here, we confirmed the inhibitory effect of FAV00A on influenza  
501 virus RNA synthesis employing influenza virus minigenome experiments (Fig. 6). Moreover,  
502 using *in vitro* influenza virus RNA polymerase assays, we demonstrated that FAV00A can  
503 directly inhibit influenza virus replication and transcription and that one of its metabolites, VR17-  
504 04, is a more potent inhibitor of influenza virus RNA synthesis than FAV00A (Fig. 6). These  
505 findings are in line with the inhibitory effect of extracts from cultured human lung cells treated  
506 with FAV00A (Fig. 5); these observations might imply that FAV00A acts on the influenza virus  
507 RNA polymerase after hydroxylation to VR17-04.

508         In summary, we have performed a single-blinded clinical trial that shows that FAV00A  
509 treatment of patients with viral respiratory infections leads to faster patient recovery and reduced  
510 virus shedding when compared to the placebo control. Our results are supported by virus  
511 infections and viral replication *in vitro* studies on cells infected with IAV and with influenza viral  
512 RNA replication assays that suggest that FAV00A can directly inhibit influenza viral replication  
513 through a hydroxylated metabolite, VR17-04. This study thus advances our understanding of

514 FAV00A and suggests that it could represent an alternative or additional treatment for current  
515 and emerging respiratory virus infections.

516

### 517 **Acknowledgements**

518 The authors thank Dr. Juergen Richt (Kansas State University, Manhattan, KS, US), Dr. Elena A.  
519 Govorkova (St. Jude Children Research Hospital, Memphis, TN, US), Dr. Peter Palese (Icahn  
520 School of Medicine at Mount Sinai (NYC, NY, US) and Adolfo Garcia-Sastre (Icahn School of  
521 Medicine at Mount Sinai, NYC, NY, US) for comments and advice.

522

### 523 **Funding**

524 The clinical trial and medical writing of the publication manuscript was funded by JSC Farmak.  
525 A.J.W. te Velhuis is supported by joint Wellcome Trust and Royal Society grant 206579/Z/17/Z  
526 and the National Institutes of Health grant R21AI147172.

527 A.M. holds an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs  
528 Wellcome Fund.

529

### 530 **Transparency declarations**

531 Aartjan te Velhuis is employed by the University of Cambridge, United Kingdom. The  
532 University of Cambridge received consulting fees for the experiments and analyses performed by  
533 Aartjan te Velhuis.

534 Megan Shaw was employed by the Icahn School of Medicine at Mount Sinai, New York, NY  
535 which received consulting fees for the experiments and analyses performed.



536 Andrew Mehle is employed by the University of Wisconsin – Madison, US. The University of  
537 Wisconsin – Madison received consulting fees for work performed for this study by Andrew  
538 Mehle.

539 Norbert Gmeinwieser received personal fees from Pharmalog Institut für klinische Forschung  
540 GmbH, subcontracted service CRO for writing the manuscript.

541 Holger Stammer received personal fees from Pharmalog Institut für klinische Forschung GmbH,  
542 subcontracted service CRO for review of the manuscript.

543 Jens Milde received personal fees from Pharmalog Institut für klinische Forschung GmbH,  
544 subcontracted service CRO for review of the manuscript.

545 Lutz Müller received personal fees from Dr. Regenold GmbH, subcontracted consultant for  
546 product development and for review of the manuscript.

547 Victor Margitich received personal fees from JSC Farmak, sponsor of the clinical trial and  
548 funding of the medical writing, for planning and coordinating the experiments and review of the  
549 manuscript.

550

## 551 **References**

- 552 1. Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. 2017. Drug resistance in  
553 influenza A virus: the epidemiology and management. *Infect Drug Resist* 10:121-134.
- 554 2. Wijnans L, Voordouw B. 2016. A review of the changes to the licensing of influenza  
555 vaccines in Europe. *Influenza Other Respir Viruses* 10:2-8.

- 556 3. Breteler JK, Tam JS, Jit M, Ket JC, De Boer MR. 2013. Efficacy and effectiveness of  
557 seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income  
558 countries: a systematic review and meta-analysis. *Vaccine* 31:5168-77.
- 559 4. van Riel D, de Wit E. 2020. Next-generation vaccine platforms for COVID-19. *Nat Mater*  
560 19:810-812.
- 561 5. Su S, Du L, Jiang S. 2020. Learning from the past: development of safe and effective  
562 COVID-19 vaccines. *Nat Rev Microbiol* doi:10.1038/s41579-020-00462-y.
- 563 6. Foley DA, Phuong LK, Englund JA. 2020. Respiratory syncytial virus immunisation  
564 overview. *J Paediatr Child Health* doi:10.1111/jpc.15232.
- 565 7. Toots M, Plemper RK. 2020. Next-generation direct-acting influenza therapeutics. *Transl*  
566 *Res* 220:33-42.
- 567 8. Mifsud EJ, Hayden FG, Hurt AC. 2019. Antivirals targeting the polymerase complex of  
568 influenza viruses. *Antiviral Res* 169:104545.
- 569 9. Goldhill DH, Te Velthuis AJW, Fletcher RA, Langat P, Zambon M, Lackenby A, Barclay  
570 WS. 2018. The mechanism of resistance to favipiravir in influenza. *Proc Natl Acad Sci U S*  
571 *A* 115:11613-11618.
- 572 10. Patel MC, Mishin VP, De La Cruz JA, Chesnokov A, Nguyen HT, Wilson MM, Barnes J,  
573 Kondor RJG, Wentworth DE, Gubareva LV. 2020. Detection of baloxavir resistant  
574 influenza A viruses using next generation sequencing and pyrosequencing methods.  
575 *Antiviral Res* 182:104906.

- 576 11. Frolov F, Golubovska O, Kramarev S, Mironenko A, Margitich V. 2018. The second birth  
577 of the drug Amizon: the results of international scientific studies confirm the antiviral  
578 effect. *Ukrainian Medical Journal* 4 (126):70-73.
- 579 12. Boltz D, Peng X, Muzzio M, Dash P, Thomas PG, Margitich V. 2018. Activity of  
580 enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated  
581 normal human bronchial epithelial cells. *Antivir Chem Chemother* 26:2040206618811416.
- 582 13. Te Velthuis AJ, Fodor E. 2016. Influenza virus RNA polymerase: insights into the  
583 mechanisms of viral RNA synthesis. *Nat Rev Microbiol* 14:479-93.
- 584 14. te Velthuis AJW, Robb NC, Kapanidis AN, Fodor E. 2016. The role of the priming loop in  
585 influenza A virus RNA synthesis. *Nat Microbiology* 1.
- 586 15. Te Velthuis AJW, Long JC, Bauer DLV, Fan RLY, Yen HL, Sharps J, Siegers JY, Killip  
587 MJ, French H, Oliva-Martin MJ, Randall RE, de Wit E, van Riel D, Poon LLM, Fodor E.  
588 2018. Mini viral RNAs act as innate immune agonists during influenza virus infection. *Nat*  
589 *Microbiol* 3:1234-1242.
- 590 16. Te Velthuis AJW, Long JS, Barclay WS. 2018. Assays to Measure the Activity of  
591 Influenza Virus Polymerase. *Methods Mol Biol* 1836:343-374.
- 592 17. Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S, Cook J,  
593 Francis NA, Lewis RJ, Godycki-Cwirko M, Llor C, Chlabicz S, Lionis C, Seifert B,  
594 Sundvall PD, Colliers A, Aabenhus R, Bjerrum L, Jonassen Harbin N, Lindbaek M, Glinz  
595 D, Bucher HC, Kovacs B, Radzeviciene Jurgute R, Touboul Lundgren P, Little P, Murphy  
596 AW, De Sutter A, Openshaw P, de Jong MD, Connor JT, Matheussen V, Ieven M,  
597 Goossens H, Verheij TJ. 2020. Oseltamivir plus usual care versus usual care for influenza-


598 like illness in primary care: an open-label, pragmatic, randomised controlled trial. *Lancet*  
599 395:42-52.

600 18. McLean HQ, Belongia EA, Kieke BA, Meece JK, Fry AM. 2015. Impact of Late  
601 Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a  
602 Randomized Trial. *Open Forum Infect Dis* 2:ofv100.

603 19. Walker AP, Fan H, Keown JR, Margitich V, Grimes JM, Fodor E, Te Velthuis AJW. 2020.  
604 Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA  
605 polymerases. *bioRxiv* doi:10.1101/2020.04.21.053017.

606


607 **Figures and legends**



608

609 **Figure 1. Patient enrollment, demographics and antigen status.** A) Schematic of patient  
 610 recruitment, randomization and treatment. B) Demographics of FAV00A- and placebo-treated  
 611 patient groups. C) Frequency of virus antigen detection in nasal swabs of patients treated with  
 612 FAV00A or placebo by immunofluorescence staining.

613



614

615 **Figure 2. FAV00A treatment reduces viral antigen levels and improves patient activity. A)**


616 Patients in whom virus antigens were not detected by immunofluorescence staining of nasal

617 swabs (%). B) Patients without routine activities (%). P values were determined by Fisher's exact

618 test.

619

620




621  
622 **Figure 3. FAV00A treatment reduces objective symptoms in patients with viral respiratory**  
623 **disease.** A) Patients without objective symptoms at different visit days (%). B) Patients without  
624 abnormal breath sounds at different visit days (%). C) Patients without pharyngeal hyperemia at  
625 different visit days (%). D) Patients without fever at different visit days (%). P values were  
626 determined by Fisher's exact test.

627

628

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .



629

630 **Figure 4. FAV00A treatment reduces subjective symptoms in patients with viral respiratory**

631 **disease.** A) Patients without subjective symptoms at different visit days (%). B) Patients without

632 at different visit days (%). C) Patients without weakness at different visit days (%). D) Patients

633 without sore throat at different visit days (%). F) Patients without cough at different visit days


634 (%). E) Patients without elevated body temperature at different visit days (%). P values were

635 determined by Fisher's exact test.

636

637





638

639 **Figure 5: Inhibition of IAV infection and RNA synthesis by enisamium in cell culture. A)**

640 Effect of FAV00A on influenza A/WSN/1933 (H1N1) virus titers in A549 cells as determined by

641 plaque assay (black line). Cytotoxicity (blue line) was determined in uninfected cells after 48 h of

642 incubation with FAV00A. B) Effect of FAV00A on influenza A/WSN/1933 (H1N1) virus titers

643 in RD cells, C) Caco-2 cells, and D) HepG2 cells as determined by micro-plaque assay (black


644 line). Cytotoxicity (percentage of live cells, blue line) was determined in uninfected cells after 48

645 h of incubation with FAV00A. Data points represent mean and standard deviation of three

646 independent FAV00A titrations and matching virus plaque experiments. E) Overview of IC<sub>50</sub>,

647 IC<sub>90</sub>, CC<sub>50</sub> and selectivity index (SI) values in different cell lines.

648



649

650 **Figure 6. FAV00A is metabolized in humans and metabolite VR17-04 inhibits the viral**

651 **RNA polymerase in vitro.** A) Effect of FAV00A on the steady-state IAV vRNA, 5S rRNA and

652 GFP levels with quantification shown in top graph. Levels of 5S rRNA and IAV vRNA were

653 analyzed by primer extension (middle panel). PA and tubulin expression were analyzed by

654 western blot (bottom panel). A mutant IAV RNA polymerase containing two amino acid

655 substitutions in the PB1 active site (PB1a) was used as negative control. Data points represent

656 mean and standard deviation of three independent FAV00A titrations and matching GFP

657 measurements or primer extensions. B) Effect of extracts from A549 cells treated with FAV00A

658 on IAV RNA polymerase activity in vitro. Five hundred or 2500 µg of FAV00A was added to

659 A549 cells for 24 h. Next, cells were lysed and 1/10 of the lysate was added to in vitro

660 polymerase assays. RNA polymerase products were analyzed by 20% denaturing PAGE. C)  
661 Quantification of the activity of the IAV RNA polymerase in vitro in the presence of FAV00A,  
662 VR17-04 or favipiravir triphosphate (T705-TP). Data points represent mean and standard  
663 deviation of three independent titrations in RNA polymerase assays. D) Phase I metabolites  
664 identified in human plasma samples. E) Activity of the IAV RNA polymerase in the presence of  
665 different VR17-04 concentrations.